Compare Adaptive Biotechnologies Corp (ADPT) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VICI Properties Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while VICI Properties Inc trades at $26.3 (market cap $29.48B). The key difference: VICI Properties Inc is far larger — about 8.9× Adaptive Biotechnologies Corp's market cap, and VICI Properties Inc pays a 6.72% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VICI | |
|---|---|---|
Market Cap | $3.33B | $29.48B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $33.93 |
52-Week Low | $10.24 | $26.09 |
Enterprise Value | $3.19B | $46.70B |
Dividend Yield | — | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VICI Properties trades at $26.70, down 1.78% on the day, reflecting a bearish technical trend. The stock shows strong fundamentals with a P/E of 9.14, a net income margin of 76.83%, and consistent earnings beats in recent quarters. Recent news highlights its investment-grade balance sheet and a 6.8% dividend yield, though technical indicators signal caution with a bearish moving average consensus.
The outlook for VICI is positive based on fundamentals, with a consensus price target of $30.67 implying 15% upside. Risks include tenant concentration and market volatility, but the company's stable cash flows and analyst buy ratings (76.9%) support a favorable long-term view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
